NEUROTROPHIC AND GLIAL MARKERS OF NERVOUS TISSUE RECOVERY IN ACUTE CEREBROVASCULAR DISORDERS: EFFECTS OF CELLULAR THERAPY WITH ANTIOXIDANT

Authors:

Abstract:

Acute cerebrovascular disorders remain one of the leading causes of mortality and disability, highlighting the relevance of finding effective approaches for neuroprotection and stimulation of neurogenesis. Therefore, studying changes in neuronal and glial markers during ischemic brain injury is of particular importance. The experiment was conducted on outbred white rats using a model of focal cerebral ischemia induced by endovascular occlusion of the middle cerebral artery. Serum levels of S100b, brain-derived neurotrophic factor, neuron-specific enolase, glial fibrillary acidic protein, and pigment epithelium-derived factor were measured to assess the effects of mesenchymal stem cells and resveratrol. It was found that acute cerebrovascular disorders are accompanied by decreased of neuron-specific enolase and pigment epithelium-derived factor and increased S100b, glial fibrillary acidic protein, and brain-derived neurotrophic factor, reflecting glial activation and adaptive responses of neural tissue. Mesenchymal stem cells monotherapy partially normalized glial activity, while combined treatment with mesenchymal stem cells and resveratrol produced a more pronounced effect: increased of neuron-specific enolase and pigment epithelium-derived factor and decreased S100b and brain-derived neurotrophic factor. This indicates restoration of neuronal metabolic activity, stimulation of angiogenesis, and optimization of glial-neuronal interactions. The novelty of the study lies in demonstrating the synergistic effect of cell-based antioxidant therapy, which enhances neuroregeneration, reduces oxidative stress, and stabilizes neurotrophic status during the early recovery period. These results are significant for the development of modern pathogenetically justified approaches to the treatment of ischemic brain injury.

Keywords:

acute cerebrovascular disorders mesenchymal stem cells resveratrol neurogenesis neuroprotection

References:

1. Canazza A, Minati L, Boffano C, Parati E, Binks S. Experimental models of brain ischemia: a review of techniques, magnetic resonance imaging, and investigational cell-based therapies. Front Neurol. 2014;5:19. doi: 10.3389/fneur.2014.00019.
2. Haupt M, Gerner ST, Bähr M, Doeppner TR. Neuroprotective Strategies for Ischemic Stroke-Future Perspectives. Int J Mol Sci. 2023 Feb 22;24(5):4334. doi: 10.3390/ijms24054334.
3. Lei W, Zhuang H, Huang W, Sun J. Neuroinflammation and energy metabolism: a dual perspective on ischemic stroke. J Transl Med. 2025 Apr 10;23(1):413. doi: 10.1186/s12967-025-06440-3.
4. Maida CD, Norrito RL, Daidone M. Neuroinflammatory mechanisms in ischemic stroke: focus on cardioembolic stroke, background, and therapeutic approaches. Int J Mol Sci. 2020;21(18):6454. doi: 10.3390/ijms21186454.
5. Moñivas Gallego E, Zurita Castillo M. Mesenchymal stem cell therapy in ischemic stroke trials: a systematic review. Regen Ther. 2024;27:301–6. doi: 10.1016/j.reth.2024.03.026.
6. Mosconi MG, Paciaroni M. Treatments in Ischemic Stroke: Current and Future. Eur Neurol. 2022;85(5):349-366. doi: 10.1159/000525822.
7. Muratova T, Khramtsov D, Stoyanov A, Vorokhta Y. Clinical epidemiology of ischemic stroke: global trends and regional differences. Georgian Med News. 2020;299:83–6. PMID: 32242851.
8. Saini V, Guada L, Yavagal DR. Global epidemiology of stroke and access to acute ischemic stroke interventions. Neurology. 2021;97(2 Suppl):6–16. doi: 10.1212/WNL.0000000000012781.
9. Shannon GS, Rinendyaputri R, Sunarno S, Malik A. Effects of stem cell therapy on preclinical stroke. Open Vet J. 2025;15(2):601–18. doi: 10.5455/OVJ.2025.v15.i2.9.
10. Singh A, Kukreti R, Saso L, Kukreti S. Oxidative stress: a key modulator in neurodegenerative diseases. Molecules. 2019;24(8):1583. doi: 10.3390/molecules24081583.
11. Szydlak R. Mesenchymal stem cells in ischemic tissue regeneration. World J Stem Cells. 2023;15(2):16–30. doi: 10.4252/wjsc.v15.i2.16.
12. Yang QQ, Zhou JW. Neuroinflammation in the central nervous system: symphony of glial cells. Glia. 2019;67(6):1017–35. doi: 10.1002/glia.23571.
13. Zhou L, Liang J, Xiong T. Research progress of mesenchymal stem cell-derived exosomes on inflammatory response after ischemic stroke. J Zhejiang Univ Med Sci. 2022;51(4):500–6. doi: 10.3724/zdxbyxb-2022-0077.
14. Zhu ZH, Jia F, Ahmed W. Neural stem cell-derived exosome as a nano-sized carrier for BDNF delivery to a rat model of ischemic stroke. Neural Regen Res. 2023;18(2):404–9. doi: 10.4103/1673-5374.346466.

Publication:

«World of Medicine and Biology» Vol. 22 No. 1 (2026) , с. 214-219
УДК 616.831-005.1-092.9:602.9:611.013.395

DOI:

https://doi.org/10.26724/2079-8334-2026-1-95-214-219